
Dyne Therapeutics, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Dyne Therapeutics is a biotechnology company developing therapies for genetically driven muscle diseases, including myotonic dystrophy and Duchenne muscular dystrophy, using its FORCE delivery platform to target muscle tissue with oligonucleotide-based drugs.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Posner Brian SDirector | Buy | $40K | 2,500at $16.00 | Oct 2, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable DYN activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.